Controlled Rosuvastatin Multinational Study in Heart Failure CORONA A Randomized, Double-Blind, Placebo Controlled Phase III Study With Rosuvastatin in Subjects With Chronic Symptomatic Systolic Heart Failure.

Trial Profile

Controlled Rosuvastatin Multinational Study in Heart Failure CORONA A Randomized, Double-Blind, Placebo Controlled Phase III Study With Rosuvastatin in Subjects With Chronic Symptomatic Systolic Heart Failure.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2015

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Angina pectoris; Cardiovascular disorders; Coronary disorders; Heart failure; Myocardial infarction; Stroke
  • Focus Biomarker; Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms CORONA; CORONA-PET
  • Sponsors AstraZeneca
  • Most Recent Events

    • 20 Nov 2013 Pooled results for competing risks for fatal/non-fatal myocardial infarction (MI), fatal/non-fatal stroke, other CV death, and non-CV death presented at the 86th Annual Scientific Sessions of the American Heart Association.
    • 15 May 2012 Results from a substudy of CORONA have been published online in the European Heart Journal, according to a BG Medicine media release.
    • 12 Sep 2011 Primary endpoint 'Coronary-flow-reserve' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top